Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

Abstract Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors o...

Full description

Bibliographic Details
Main Authors: Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Pulmonary Medicine
Subjects:
Asthma
Mepolizumab
Eosinophilic chronic rhinosinusitis
Predictive factor
Staphylococcus enterotoxin
Online Access:http://link.springer.com/article/10.1186/s12890-019-0952-1

Internet

http://link.springer.com/article/10.1186/s12890-019-0952-1

Similar Items